KIT and gastrointestinal stromal tumor: We evaluated the effects of MK-1775 and avapritinib using the GIST-T1+Cas9 (KIT driven) and GIST-T1+D842V KITKO (PDGFRA driven) cell lines, as single agents and in combination at increasing molar ratios.